GSK and Theravance announce positive results from studies comparing ANORO™ ELLIPTA™ with SERETIDE® DISKUS®and ADVAIR® DISKUS® in patients with COPD GlaxoSmithKline plc (LSE/NYSE: GSK) and Theravance, ...

New study shows that rate of patient persistence using Sandoz AirFluSal Forspiro is twice as high as for reference product Seretide® Diskus®. Study highlights importance of improving treatment ...

GlaxoSmithKline has received approval in Japan for its key respiratory product Seretide/Advair Diskus and its anti-thrombotic Arixtra, a move which the company says should make a significant ...

Introduction: The incidence of asthma exacerbations in patients receiving salmeterol/fluticasone propionate (Seretide™ or Advair ®) is low. However, when asthma control deteriorates, clinicians may ...

Results of the European INSPIRE (Investigating New Standards for Prophylaxis in Reduction of Exacerbations) study, published in the American Journal of Respiratory and Critical Care Medicine (2008: ...

Lagos — GLAXOSMITHKLINE Pharmaceutical Nigeria Plc (GSK), one of the leading pharmaceutical companies would today launch its anti-asthmatic drug seretide diskus, in the country. According to a ...

Seretide diskus, a combination inhaler and the world's biggest selling anti-asthmatic medication from the stable of GlaxoSmithkline Pharmaceutical Nigeria PLC (GSK), is set to be launched into the ...

Mylan has become the first company to launch a generic version of GlaxoSmithKline's (GSK) big-selling respiratory drug Seretide in the UK. Seretide (salmeterol xinafoate/fluticasone propionate) – sold ...

This study has demonstrated that doubling the dose of Seretide™ administered via the Diskus™ inhaler over a short period is safe and well tolerated. Whilst this is not a recommended treatment approach ...